Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 University of Queensland Centre for Youth Substance Abuse Research, Brisbane, Australia; 2 National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
Список исп. литературыСкрыть список
1.United Nations Office on Drugs and Crime. World drug report 2019. Vienna: United Nations, 2019.
2.Peacock A, Leung J, Larney S et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction 2018;113:1905-26.
3.Room R, Fischer B, Hall WD et al. Cannabis policy: moving beyond stalemate. Oxford: Oxford University Press, 2010.
4.Kilmer B, MacCoun RJ. How medical marijuana smoothed the transition to marijuana legalization in the United States. Annu Rev Law Soc Sci 2017;13:181-202.
5.Felson J, Adamczyk A, Thomas C. How and why have attitudes about cannabis legalization changed so much? Soc Sci Res 2019;78:12-27.
6.Degenhardt L, Whiteford HA, Ferrari AJ et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1564-74.
7.Global Burden of Disease 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1345-422.
8.Caulkins J, Kilmer B, Kleiman M et al. Considering marijuana legalization: insights for Vermont and other jurisdictions. Santa Monica: RAND Corporation, 2015.
9.Garvey T, Yeh BT. State legalization of recreational marijuana: selected legal issues. Washington: Congressional Research Office, 2014.
10.US Government Accountability Office. State marijuana legalization, DOJ should document its approach to monitoring the effects of legalization. Washington: US Government Accountability Office, 2015.
11.Hall WD. Alcohol and cannabis: comparing their adverse health effects and regulatory regimes. Int J Drug Policy 2017;42:57-62.
12.Room R. Legalizing a market for cannabis for pleasure: Colorado, Washington, Uruguay and beyond. Addiction 2014;109:345-51.
13.Pardo B. Cannabis policy reforms in the Americas: a comparative analysis of Colorado, Washington, and Uruguay. Int J Drug Policy 2014;25:727-35.
14.Wallach PA, Hudak J. Legal marijuana: comparing Washington and Colorado. Washington: Brookings Institution, 2014.
15.Quinn S. Alaska allows recreational marijuana as legalization campaign spreads. Reuters, February 24, 2015.
16.Wallach PA. Washington’s marijuana legalization grows knowledge, not just pot. Washington: Brookings Institution and the Washington Office on Latin America, 2014.
17.Smart R, Caulkins JP, Kilmer B et al. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction 2017;112:2167-77.
18.Hudak J, Ramsey G, Walsh J. Uruguay’s cannabis law: pioneering a new paradigm. Washington: Center for Effective Public Management at Brookings, 2018.
19.Cerdá M, Kilmer B. Uruguay’s middle-ground approach to cannabis legalization. Int J Drug Policy 2017;42:118-20.
20.Walsh J, Ramsey G. Cannabis regulation in Uruguay: an innovative law facing major challenges. J Drug Policy Anal 2016;11.
21.Ramsey G. Getting regulation right: assessing Uruguay’s historic cannabis initiative. Washington: WOLA Advocacy for Human Rights in the Americas, 2016.
22.Instituto de Regulacion y Control de Cannabis. Mercado regulado de cannabis informe VII al 30/06/19. Montevideo: Instituto de Regulacion y Control de Cannabis, 2019.
23.Cox C. The Canadian Cannabis Act legalizes and regulates recreational cannabis use in 2018. Health Policy 2018;122:205-9.
24.Government of Canada. Cannabis Act (S.C. 2018, c. 16). Ottawa: Department of Justice, 2018.
25.Government of Canada. Cannabis legalization and regulation: cannabis is now legal. Ottawa: Department of Justice, 2018.
26.Watson TM, Hyshka E, Bonato S et al. Early-stage cannabis regulatory policy planning across Canada’s four largest provinces: a descriptive overview. Subst Use Misuse 2019;54:1691-704.
27.Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol 2019;30:98-102.
28.Swanson A, Gamio L. How the price of pot differs in 50 states and 8 major cities. Washington Post, June 22, 2015.
29.Caulkins JP, Hawken A, Kilmer B et al. Marijuana legalization: what everyone needs to know. New York: Oxford University Press, 2012.
30.Subritzky T, Pettigrew S, Lenton S. Issues in the implementation and evolution of the commercial recreational cannabis market in Colorado. Int J Drug Policy 2016;27:1-12.
31.Babor T, Caetano R, Casswell S et al. Alcohol: no ordinary commodity: research and public policy, 2nd ed. Oxford: Oxford University Press, 2010.
32.Chaloupka FJ, Warner KE. The economics of smoking. In: Newhouse JP, Cuyler AJ (eds). The handbook of health economics. New York: Elsevier, 2000:1539-627.
33.Statistics Canada. Analysis of trends in the prevalence of cannabis use and related metrics in Canada. Ottawa: Government of Canada, 2019.
34.Statistics Canada. National cannabis survey, first quarter 2019. Ottawa: Government of Canada, 2019.
35.Babor T, Caulkins JP, Fischer B et al. Drug policy and the public good, 2nd ed. New York: Oxford University Press, 2018.
36.Hall WD, Renström M, Poznyak V. The health and social effects of nonmedical cannabis use. Geneva: World Health Organization, 2016.
37.National Academies of Sciences Engineering and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington: National Academies Press for the National Academies of Sciences Engineering and Medicine, 2017.
38.Fischer B, Russell C, Rehm J et al. Assessing the public health impact of cannabis legalization in Canada: core outcome indicators towards an ‘index’ for monitoring and evaluation. J Public Health 2019;41:412-21.
39.Hall WD, Lynskey M. Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction 2016;111:1764-73.
40.Windle SB, Wade K, Filion KB et al. Potential harms from legalization of recreational cannabis use in Canada. Can J Public Health 2019;110:222-6.
41.Volkow ND, Han B, Compton WM et al. Self-reported medical and nonmedical cannabis use among pregnant women in the United States. JAMA 2019;322:167-9.
42.Choo EK, Emery SL. Clearing the haze: the complexities and challenges of research on state marijuana laws. Ann NY Acad Sci 2017;1394:55-73.
43.Budney AJ, Sofis MJ, Borodovsky JT. An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use. Eur Arch Psychiatry Clin Neurosci 2019;269:73-86.
44.Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med 2015;45:3181-9.
45.Scott JC, Slomiak ST, Jones JD et al. Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry 2018;75:585-95.
46.Horwood L, Fergusson D, Hayatbakhsh M et al. Cannabis use and educational achievement: findings from three Australasian cohort studies. Drug Alcohol Depend 2010;110:247-53.
47.Auer R, Vittinghoff E, Yaffe K et al. Association between lifetime marijuana use and cognitive function in middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. JAMA Intern Med 2016;176:352-61.
48.Marconi A, Di Forti M, Lewis CM et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 2016;42:1262-9.
49.Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry 2016;79:549-56.
50.Di Forti M, Marconi A, Carra E et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2015;2:233-8.
51.Large M, Sharma S, Compton MT et al. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 2011;68:555-61.
52.Schoeler T, Monk A, Sami MB et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 2016;3:215-25.
53.Di Forti M, Quattrone D, Freeman TP et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 2019;6:427-36.
54.Allen JH, de Moore GM, Heddle R et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004;53:1566-70.
55.Simonetto DA, Oxentenko AS, Herman ML et al. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc 2012;87:114-9.
56.Khattar N, Routsolias JC. Emergency department treatment of cannabinoid hyperemesis syndrome: a review. Am J Ther 2018;25:e357-61.
57.Nourbakhsh M, Miller A, Gofton J et al. Cannabinoid hyperemesis syndrome: reports of fatal cases. J Forensic Sci 2019;64:270-4.
58.Jouanjus E, Lapeyre-Mestre M, Micallef J. Cannabis use: signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc 2014;3:e000638.
59.Arora S, Goyal H, Aggarwal P et al. ST-segment elevation myocardial infarction in a 37-year-old man with normal coronaries – it is not always cocaine! Am J Emerg Med 2012;30:2091.e3-5.
60.Casier I, Vanduynhoven P, Haine S et al. Is recent cannabis use associated with acute coronary syndromes? An illustrative case series. Acta Cardiol 2014;69:131-6.
61.Hodcroft CJ, Rossiter MC, Buch AN. Cannabis-associated myocardial infarction in a young man with normal coronary arteries. J Emerg Med 2014;47:277-81.
62.Aronow W, Cassidy J. Effect of marihuana and placebo marihuana smoking on angina pectoris. N Engl J Med 1974;291:65-7.
63.Mittleman MA, Lewis R, Maclure M et al. Triggering myocardial infarction by marijuana. Circulation 2001;103:2805-9.
64.Mukamal K, Maclure M, Muller J et al. An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J 2008;155:
65.Frost L, Mostofsky E, Rosenbloom JI et al. Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am Heart J 2013;165:170-5.
66.Aldington S, Williams M, Nowitz M et al. Effects of cannabis on pulmonary structure, function and symptoms. Thorax 2007;62:1058-63.
67.Bloom J, Kaltenborn W, Paoletti P et al. Respiratory effects of non-tobacco cigarettes. BMJ 1987;295:1516-8.
68.Moore BA, Augustson EM, Moser RP et al. Respiratory effects of marijuana and tobacco use in a U.S. sample. J Gen Intern Med 2005;20:33-7.
69.Tan WC, Lo C, Jong A et al. Marijuana and chronic obstructive lung disease: a population-based study. Can Med Assoc J 2009;180:814-20.
70.Tashkin DP, Coulson AH, Clark VA et al. Respiratory symptoms and lung function in habitual heavy smokers of marijuana alone, smokers of marijuana and tobacco, smokers of tobacco alone, and non-smokers. Am Rev Respir Dis 1987;135:209-16.
71.Taylor DR, Poulton R, Moffitt T et al. The respiratory effects of cannabis dependence in young adults. Addiction 2000;95:1669-77.
72.Hancox RJ, Shin HH, Gray AR et al. Effects of quitting cannabis on respiratory symptoms. Eur Respir J 2015;46:80-7.
73.Kempker JA, Honig EG, Martin GS. The effects of marijuana exposure on expiratory airflow. A study of adults who participated in the U.S. National Health and Nutrition Examination Study. Ann Am Thorac Soc 2015;12:135-41.
74.Berthiller J, Straif K, Boniol M et al. Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. J Thorac Oncol 2008;3:1398-403.
75.Zhang LR, Morgenstern H, Greenland S et al. Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium. Int J Cancer 2015;136:894-903.
76.Gurney J, Shaw C, Stanley J et al. Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer 2015;15:897.
77.Smart R, Pacula RL. Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: findings from state policy evaluations. Am J Drug Alcohol Abuse 2019;45:644-63.
78.Pacula RL, Kilmer B, Wagenaar AC et al. Developing public health regulations for marijuana: lessons from alcohol and tobacco. Am J Public Health 2014;104:1021-8.
79.Pacula RL. Examining the impact of marijuana legalization on marijuana consumption: insights from the economics literature. Santa Monica: RAND Corporation, 2010.
80.Kilmer B, Caulkins JP, Pacula RL et al. Altered state? Assessing how marijuana legalization in California could influence marijuana consumption and public budgets. Santa Monica: RAND Drug Policy Research Center, 2010.
81.Cerdá M, Mauro C, Hamilton A et al. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry 2020;77:165-71.
82.Everson EM, Dilley JA, Maher JE et al. Post-legalization opening of retail cannabis stores and adult cannabis use in Washington State, 2009-2016. Am J Public Health 2019;109:1294-301.
83.Cerdá M, Wall M, Feng T et al. Association of state recreational marijuana laws with adolescent marijuana use. JAMA Pediatr 2017;171:142-9.
84.Kerr WC, Ye Y, Subbaraman MS et al. Changes in marijuana use across the 2012 Washington State recreational legalization: is retrospective assessment of use before legalization more accurate? J Stud Alcohol Drugs 2018;79:495-502.
85.Darnell AJ, Bitney K. I-502 evaluation and benefit-cost analysis: second required report. Olympia: Washington State Institute for Public Policy, 2017.
86.Anderson DM, Hansen B, Rees DI et al. Association of marijuana laws with teen marijuana use: new estimates from the Youth Risk Behavior Surveys. JAMA Pediatr 2019;173:879-81.
87.Dilley JA, Richardson SM, Kilmer B et al. Prevalence of cannabis use in youths after legalization in Washington State. JAMA Pediatr 2019;173:192-3.
88.Wang GS, Hall K, Vigil D et al. Marijuana and acute health care contacts in Colorado. Prev Med 2017;104:24-30.
89.Davis JM, Mendelson B, Berkes JJ et al. Public health effects of medical marijuana legalization in Colorado. Am J Prev Med 2016;50:373-9.
90.Delling FN, Vittinghoff E, Dewland TA et al. Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA. BMJ Open 2019;9:e027432.
91.Sokoya M, Eagles J, Okland T et al. Patterns of facial trauma before and after legalization of marijuana in Denver, Colorado: a joint study between two Denver hospitals. Am J Emerg Med 2018;36:780-3.
92.Heard K, Monte AA, Hoyte CO. Brief commentary: consequences of marijuana – observations from the emergency department. Ann Intern Med 2019;170:124.
93.Bhandari S, Jha P, Lisdahl KM et al. Recent trends in cyclic vomiting syndrome-associated hospitalisations with liberalisation of cannabis use in the state of Colorado. Intern Med J 2019; 49:649-55.
94.Monte AA, Zane RD, Heard KJ. The implications of marijuana legalization in Colorado. JAMA 2015;313:241-2.
95.Calcaterra SL, Hopfer CJ, Keniston A et al. Changes in healthcare encounter rates possibly related to cannabis or alcohol following legalization of recreational marijuana in a safety-net hospital: an interrupted time series analysis. J Addict Med 2019;13:201-8.
96.Hall KE, Monte AA, Chang T et al. Mental health-related emergency department visits associated with cannabis in Colorado. Acad Emerg Med 2018;25:526-37.
97.Richards JR, Smith NE, Moulin AK. Unintentional cannabis ingestion in children: a systematic review. J Pediatr 2017;190:142-52.
98.Koski L. Retail marijuana product manufacturing, packaging, and labeling compliance guidance. Lakewood: Marijuana Enforcement Division, 2017.
99.Whitehill JM, Harrington C, Lang CJ et al. Incidence of pediatric cannabis exposure among children and teenagers aged 0 to 19 years before and after medical marijuana legalization in Massachusetts. JAMA Netw Open 2019;2:e199456.
100.Chung C, Salottolo K, Tanner A, et al. The impact of recreational marijuana commercialization on traumatic injury. Inj Epidemiol 2019;6:3.
101.Aydelotte JD, Brown LH, Luftman KM et al. Crash fatality rates after recreational marijuana legalization in Washington and Colorado. Am J Public Health 2017;107:1329-31.
102.Sevigny EL. The effects of medical marijuana laws on cannabis-involved driving. Accid Anal Prev 2018;118:57-65.
103.Lane TJ, Hall W. Traffic fatalities within US states that have legalized recreational cannabis sales and their neighbours. Addiction 2019;114:847-56.
104.Jouanjus E, Leymarie F, Tubery M et al. Cannabis-related hospitalizations: unexpected serious events identified through hospital databases. Br J Clin Pharmacol 2011;71:758-65.
105.Wolff V, Armspach JP, Lauer V et al. Ischaemic strokes with reversible vasoconstriction and without thunderclap headache: a variant of the reversible cerebral vasoconstriction syndrome? Cerebrovasc Dis 2015;39:31-8.
106.Wolff V, Lauer V, Rouyer O et al. Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. Stroke 2011;42:1778-80.
107.Plunk AD, Peglow SL, Harrell PT et al. Youth and adult arrests for cannabis possession after decriminalization and legalization of cannabis. JAMA Pediatr 2019;173:763-9.
108.US Substance Abuse and Mental Health Services Administration. N-SSATS quick statistics state profiles. Rockville: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, 2015.
109.Becker J, Schaub MP, Gmel G et al. Cannabis use and other predictors of the onset of daily cigarette use in young men: what matters most? Results from a longitudinal study. BMC Public Health 2015;15:1-10.
110.Males M, Buchen L. Reforming marijuana laws: which approach best reduces the harms of criminalization? A five state analysis. San Francisco: Centre on Juvenile and Criminal Justice, 2014.
111.Black P, Joseph LJ. Still dazed and confused: midlife marijuana use by the baby boom generation. Deviant Behav 2014;35:822-41.
112.Han BH, Sherman S, Mauro PM et al. Demographic trends among older cannabis users in the United States, 2006-13. Addiction 2017;112:516-25.
113.Bachman J, Wadsworth K, O’Malley P et al. Smoking, drinking, and drug use in young adulthood: the impacts of new freedoms and new responsibilities. Mahwah: Lawrence Erlbaum, 1997.
114.Terry-McElrath YM, Patrick ME, O’Malley PM et al. The end of convergence in developmental patterns of frequent marijuana use from ages 18 to 30: an analysis of cohort change from 1976-2016. Drug Alcohol Depend 2018;191:203-9.
115.Shover CL, Humphreys K. Six policy lessons relevant to cannabis legalization. Am J Drug Alcohol Abuse 2019;45:698-706.
116.Fischer B, Russell C, Sabioni P et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health 2017;107: